Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: Possible roles in tumor progression and metastasis
- 1 July 1991
- journal article
- Published by Elsevier BV in Thrombosis Research
- Vol. 63 (1), 59-71
- https://doi.org/10.1016/0049-3848(91)90270-7
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCERThe Lancet, 1989
- Down‐regulation of proteolytic activity in 12‐O‐tetradecanoyl‐phorbol‐13‐acetate‐induced k562 leukemia cell cultures: Depletion of active urokinase by excess type 1 plasminogen activator inhibitorJournal of Cellular Physiology, 1989
- Comparative study of plasminogen activator antigens in colonic carcinomas and adenomasInternational Journal of Cancer, 1988
- Autocrine saturation of pro-urokinase receptors on human A431 cellsCell, 1986
- Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.The Journal of cell biology, 1986
- The receptor for urokinase‐plasminogen activatorJournal of Cellular Biochemistry, 1986
- Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomasInternational Journal of Cancer, 1984
- Plasminogen Activator Released as Inactive Proenzyme from Murine Cells Transformed by Sarcoma VirusEuropean Journal of Biochemistry, 1982
- Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7)Biochemical and Biophysical Research Communications, 1979
- A study of proteases and protease-inhibitor complexes in biological fluidsThe Journal of Experimental Medicine, 1978